AFLIBERCEPT (Eylea) prior authorization at Regence
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Regence requires Vascular Endothelial Growth Factor Inhibitor prior-authorization documentation for AFLIBERCEPT (Eylea): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return on the clock printed in the current member-specific payer source; if denied, use the appeal window printed on the denial notice to appeal.
The PA criteria you'll need to meet
Regence reviews AFLIBERCEPT (Eylea) prior authorizations against its medical policy for Vascular Endothelial Growth Factor Inhibitor. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Vascular Endothelial Growth Factor Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Regence's medical policy URL referenced in the cover letter
Denial scenarios to check against the current policy
These are preparation scenarios, not frequency claims. Use only those supported by the current member-specific source:
- Cross-state coordination for multi-state members (OR/WA/ID/UT)
- Step therapy via Prime Therapeutics
- Behavioral health network adequacy
- Specialty drug PA
AFLIBERCEPT (Eylea)-specific review scenarios and context
Check whether the current notice cites any of these label-, REMS-, or policy-related scenarios:
- Step therapy requiring bevacizumab (Avastin off-label) first per UnitedHealthcare/Aetna policies
- Quantity limit on injections per eye per year
- High-dose Eylea HD denied (8mg formulation)
- Site-of-care reduction
Brand: Eylea. Anti-VEGF for wet AMD, DME, DR, RVO. Eylea HD (8mg, FDA-approved August 2023) enables longer dosing intervals. Biosimilars Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) launched 2024.
Manufacturer patient-assistance program: EylEA4U — relevant when a Regence denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Verify the appeal window and decision clock in the current denial notice and member-specific payer source before relying on either. Submit through the provider portal (https://www.regence.com/provider) with the same packet plus an applicable, current clinical source supporting AFLIBERCEPT (Eylea)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Regence denial on DenialHelp.
Contact Regence
- Provider portal: https://www.regence.com/provider
Frequently asked questions
What documentation does Regence need for AFLIBERCEPT (Eylea) prior auth?
Regence's typical PA packet for AFLIBERCEPT (Eylea): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Vascular Endothelial Growth Factor Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Regence?
Verify the decision clock in the current member-specific payer policy and request receipt. Product type, urgency, state law, and plan terms can change the applicable timing; this page does not supply an operational deadline.
What documentation issues should be checked for AFLIBERCEPT (Eylea) at Regence?
Preparation scenarios to check against the current notice and policy include: Cross-state coordination for multi-state members (OR/WA/ID/UT); Step therapy via Prime Therapeutics; Behavioral health network adequacy. These are not measured frequency claims. For AFLIBERCEPT (Eylea), verify whether the actual denial raises step therapy, indication, or another plan-specific criterion before responding.
How do I prep for a peer-to-peer with Regence on AFLIBERCEPT (Eylea)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the AFLIBERCEPT (Eylea) PA packet
Open ApprovalHelp — generate a AFLIBERCEPT (Eylea) prior-auth packet tailored to Regence's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com